General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RSBMJ
ADC Name
Sofituzumab vedotin
Synonyms
Anti-MUC16 ADC MMAE; Anti-MUC16 MMAE ADC; Anti-MUC16 mAb MMAE; Anti-MUC16 monoclonal antibody MMAE; Anti-MUC16 monoclonal antibody monomethyl auristatin E conjugate; Anti-MUC16 monoclonal antibody vedotin; DMUC-5754A; DMUC5754A; MMAE anti-MUC16; MMAE anti-MUC16 mAb; RG-7458; RG7458, DMUC 5754A; Sofituzumab vedotin
   Click to Show/Hide
Organization
Genentech, Inc.; Roche Holding AG
Drug Status
Phase 1 (Terminated)
Indication
In total 2 Indication(s)
Ovarian cancer
Phase 1
Clinical Trial
Pancreatic cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
3 to 4
Structure
Antibody Name
Anti-MUC16 Anti-ody 3A5
 Antibody Info 
Antigen Name
Mucin-16 (MUC16)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mc-Val-Cit-PABC
 Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
Puchem SID
472406306 , 223370458 , 312468222 , 384585219 , 404772778
Drugbank ID
DB15349
ChEBI ID
CHEMBL3545372